Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 25, 2021Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial
-
Oct 22, 2021Pivotal trial met primary and all key secondary endpoints
-
Oct 20, 2021Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
-
Aug 30, 2021Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks
-
Aug 6, 2021Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile
-
Jun 28, 2021* Study also shows more people on Soliqua 100/33 had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin
-
Jun 28, 2021- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2
-
Jun 17, 2021* $425 million investment in Sanofi's Swiftwater, PA facility expands production of Fluzone® High-Dose Quadrivalent for people 65 and older in the U.S.
-
Jun 1, 2021* This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
May 17, 2021- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients